TOP HEADLINES

Featured Story

  • J&J looks to sell off Cordis for as much as $2B

    Johnson & Johnson is reportedly seeking a buyer for its Cordis unit, which is focused on vascular medical devices. This would be the second major divestiture for the conglomerate this year, it sold Ortho-Clinical Diagnostics to private equity firm The Carlyle Group in June for $4.2 billion.

J&J shoring up for latest courtroom battle over all-metal hip implant

Long beleaguered by claims related to defective all-metal hip implants, Johnson & Johnson is shoring up for its latest courtroom battle as the company faces the first trial for one of its artificial hip devices.

ArthroCare $750M fraud saga culminates in decades-long prison term

Cooking the books doesn't pay. That's the message the U.S. Department of Justice sent with the strict sentence it got for ArthroCare executives—albeit almost a decade after the problematic bookkeeping practices began.

St. Jude emphasizes cardiology guidewires, technology for fractional flow reserve

St. Jude Medical's data dump at the European Society of Cardiology Congress in Barcelona, Spain, was heartening news for the company's products--especially those used to measure a ratio known as fractional flow reserve.

Dime-sized device can separate healthy and cancerous cells

MIT scientists have developed a dime-sized microfluidic device that can sort rare cancer cells from healthy ones using sound waves--an innovation that could have applications for cancer diagnosis, drug discovery and clinical research.

Can the nose bone be connected to the knee bone?

Researchers at the University and University Hospital of Basel in Switzerland report they have taken cartilage cells from nasal septums and successfully generated new cartilage that was used to repair damaged knees in patients.

MORE NEWS

From Our Sister Sites

FierceDiagnostics

NanoString Technologies' chief medical officer died unexpectedly, the Seattle maker of molecular diagnostic products and research tools disclosed recently.

FierceVaccines

Back in June, Amgen said it was eyeing a U.S. application for its cancer-fighting viral vaccine in the short term but would be looking outside the U.S. as well. After submitting its candidate to the FDA in July, the company now says it's turned over a marketing authorization application to the European Medicines Agency for the melanoma candidate.